Previous 10 | Next 10 |
home / stock / mmed:cc / mmed:cc news
MindMed Announces Completion of Share Redesignation Canada NewsWire NEW YORK , June 30, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) ("MindMed'' or the "Company") announces that it has completed its previously announced redesignat...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of mental health conditions. The Tesla CEO said ...
Mindmed Announces Voting Results for Annual General and Special Meeting Canada NewsWire NEW YORK , June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's ...
MindMed to Participate in the Jefferies Global Healthcare Conference Canada NewsWire NEW YORK , June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company develo...
MindMed Appoints Schond L. Greenway as Chief Financial Officer Canada NewsWire NEW YORK , May 23, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developin...
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal Canada NewsWire - Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing sup...
MindMed Announces At-The-Market Offering Canada NewsWire NEW YORK , May 16, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health ...
Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) announced Monday its financial results for the first quarter of 2022. MindMed is a New York-based psychedelic medicine biotechnology company that develops psychedelic-inspired drugs and therapies to combat addiction and mental illn...
MindMed Reports First Quarter 2022 Financial Results and Business Highlights Canada NewsWire - Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal , MD as Chief Commercial Of...
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management Canada NewsWire - Webinar to feature presentations from Kelly E. Dunn , PhD, MBA, and Stuart Gitlow , MD, MPH, MBA, on Thursday, May 19 at 11:00am EDT - ...
News, Short Squeeze, Breakout and More Instantly...
Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as w...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the...
All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...